At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NVCR NovoCure
Not Yet Opened 03-23 16:00:00 EDT
11.82
+0.01
+0.08%
盘后12.05
+0.23+1.95%
19:16 EDT
High12.19Low11.63Vol1.55M
Open11.94D1 Closing11.81Amplitude4.75%
Mkt Cap1.35BTradable Cap1.11BTotal Shares114.00M
T/O18.36MT/O Rate1.64%Tradable Shares94.15M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Should Japan’s Optune Lua Reimbursement Win Reframe NovoCure’s (NVCR) Access and Utilization Story?
Simply Wall St.  ·  03-10
Should Japan’s Optune Lua Reimbursement Win Reframe NovoCure’s (NVCR) Access and Utilization Story?
NovoCure (NVCR) Is Up 24.5% After FDA Approval Of Optune Pax And 2026 Guidance Update
Simply Wall St.  ·  03-03
NovoCure (NVCR) Is Up 24.5% After FDA Approval Of Optune Pax And 2026 Guidance Update
Japan approves national reimbursement for Novocure's Optune Lua in NSCLC
Reuters  ·  03-02
Japan approves national reimbursement for Novocure's Optune Lua in NSCLC
Novocure Ltd - Optune Lua Approved for Use With Pd-1/Pd-L1 Inhibitors in Japan
THOMSON REUTERS  ·  03-02
Novocure Ltd - Optune Lua Approved for Use With Pd-1/Pd-L1 Inhibitors in Japan
Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer
THOMSON REUTERS  ·  03-02
Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer
Novocure Ltd - to Launch Optune Lua in Japan With Reimbursement
THOMSON REUTERS  ·  03-02
Novocure Ltd - to Launch Optune Lua in Japan With Reimbursement
NovoCure Earnings Call: Growth Builds Amid Profit Strain
TIPRANKS  ·  03-02
NovoCure Earnings Call: Growth Builds Amid Profit Strain
Novocure to Participate in Leerink Global Healthcare Conference
Reuters  ·  02-28
Novocure to Participate in Leerink Global Healthcare Conference
Novocure Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  02-27
Novocure Is Maintained at Buy by HC Wainwright & Co.
Novocure Ltd reports results for the quarter ended December 31 - Earnings Summary
Reuters  ·  02-26
Novocure Ltd reports results for the quarter ended December 31 - Earnings Summary
Stock Track | NovoCure Plunges 7.4% Pre-Market on Margin Pressure and Weak EBITDA Outlook
Stock Track  ·  02-26
Stock Track | NovoCure Plunges 7.4% Pre-Market on Margin Pressure and Weak EBITDA Outlook
Earnings Flash (NVCR) Novocure Reports Q4 Loss $0.22 a Share, vs. FactSet Est of $0.41 Loss
MT Newswires Live  ·  02-26
Earnings Flash (NVCR) Novocure Reports Q4 Loss $0.22 a Share, vs. FactSet Est of $0.41 Loss
Novocure Q4 revenue slightly beats expectations, margins drop
Reuters  ·  02-26
Novocure Q4 revenue slightly beats expectations, margins drop
Novocure Q4 Revenue USD 174.35 Million Vs. IBES Estimate USD 173.4 Million
Reuters  ·  02-26
Novocure Q4 Revenue USD 174.35 Million Vs. IBES Estimate USD 173.4 Million
Novocure Q4 net loss hits USD 24.5 million as R&D spending rises 19% to USD 60.9 million
Reuters  ·  02-26
Novocure Q4 net loss hits USD 24.5 million as R&D spending rises 19% to USD 60.9 million
Novocure Q4 Pretax Profit USD -40.954 Million
THOMSON REUTERS  ·  02-26
Novocure Q4 Pretax Profit USD -40.954 Million
Novocure Ltd: Outlook 2026 Adj Ebitda $-20 Mln - $0 Mln
THOMSON REUTERS  ·  02-26
Novocure Ltd: Outlook 2026 Adj Ebitda $-20 Mln - $0 Mln
Novocure Ltd - 2026 Revenue Guidance $675 Mln-$705 Mln
THOMSON REUTERS  ·  02-26
Novocure Ltd - 2026 Revenue Guidance $675 Mln-$705 Mln
Today’s Market Recap: AI Momentum Lifts U.S. Markets as Tariff Battles and Global Trade Tensions Unfold
TradingKey  ·  02-26
Today’s Market Recap: AI Momentum Lifts U.S. Markets as Tariff Battles and Global Trade Tensions Unfold
NovoCure Up Over 27%, On Pace for Largest Percent Increase Since December 2024 -- Data Talk
Dow Jones  ·  02-26
NovoCure Up Over 27%, On Pace for Largest Percent Increase Since December 2024 -- Data Talk

Introduction

Company Name.
NovoCure
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Issue price:
--